甘李药业：全资子公司获GLR1044注射液药物临床试验批准

Core Viewpoint - Ganli Pharmaceutical announced that its wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for the investigational drug GLR1044 injection, which is intended for the treatment of moderate to severe atopic dermatitis in adults [1] Group 1: Product Development - The product GLR1044 is a biosimilar to Dupilumab [1] - As of September 30, 2025, the company has invested a total of 65.7245 million yuan in research and development for this project [1] Group 2: Market Context - Currently, only the original manufacturer Sanofi's Dupilumab injection has been approved for market release in China [1] - The global sales of Dupilumab are projected to be 13.072 billion euros for the fiscal year 2024 [1]